468 related articles for article (PubMed ID: 27515310)
1. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
Nile DL; Rae C; Hyndman IJ; Gaze MN; Mairs RJ
BMC Cancer; 2016 Aug; 16():621. PubMed ID: 27515310
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
[TBL] [Abstract][Full Text] [Related]
3. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
[TBL] [Abstract][Full Text] [Related]
4. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
5. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
[TBL] [Abstract][Full Text] [Related]
6. The combination of olaparib and camptothecin for effective radiosensitization.
Miura K; Sakata K; Someya M; Matsumoto Y; Matsumoto H; Takahashi A; Hareyama M
Radiat Oncol; 2012 Apr; 7():62. PubMed ID: 22524618
[TBL] [Abstract][Full Text] [Related]
7. Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation.
Hirai T; Shirai H; Fujimori H; Okayasu R; Sasai K; Masutani M
Cancer Sci; 2012 Jun; 103(6):1045-50. PubMed ID: 22404155
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality.
Jiang Y; Verbiest T; Devery AM; Bokobza SM; Weber AM; Leszczynska KB; Hammond EM; Ryan AJ
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):772-81. PubMed ID: 27020103
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.
Camero S; Ceccarelli S; De Felice F; Marampon F; Mannarino O; Camicia L; Vescarelli E; Pontecorvi P; Pizer B; Shukla R; Schiavetti A; Mollace MG; Pizzuti A; Tombolini V; Marchese C; Megiorni F; Dominici C
J Cancer Res Clin Oncol; 2019 Jan; 145(1):137-152. PubMed ID: 30357520
[TBL] [Abstract][Full Text] [Related]
11. PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation.
Kageyama SI; Junyan D; Hojo H; Motegi A; Nakamura M; Tsuchihara K; Akimoto T
J Radiat Res; 2020 Mar; 61(2):177-186. PubMed ID: 31976528
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.
Mao Y; Huang X; Shuang Z; Lin G; Wang J; Duan F; Chen J; Li S
Cancer Med; 2018 Apr; 7(4):1285-1296. PubMed ID: 29479816
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors.
Mangoni M; Sottili M; Salvatore G; Meattini I; Desideri I; Greto D; Loi M; Becherini C; Garlatti P; Delli Paoli C; Dominici L; Gerini C; Scoccianti S; Bonomo P; Silvano A; Beltrami G; Campanacci D; Livi L
Radiat Res; 2018 Nov; 190(5):464-472. PubMed ID: 30067444
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.
Karnak D; Engelke CG; Parsels LA; Kausar T; Wei D; Robertson JR; Marsh KB; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
Clin Cancer Res; 2014 Oct; 20(19):5085-96. PubMed ID: 25117293
[TBL] [Abstract][Full Text] [Related]
16. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wang W; Duan B; Zeng L
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
[TBL] [Abstract][Full Text] [Related]
17. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1659-1670. PubMed ID: 32279088
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of Deubiquitylating Enzymes in the Cellular Response to High-LET Ionizing Radiation and Complex DNA Damage.
Carter RJ; Nickson CM; Thompson JM; Kacperek A; Hill MA; Parsons JL
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):656-665. PubMed ID: 30851349
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines.
Waissi W; Amé JC; Mura C; Noël G; Burckel H
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201963
[TBL] [Abstract][Full Text] [Related]
20. PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.
Liu Q; Gheorghiu L; Drumm M; Clayman R; Eidelman A; Wszolek MF; Olumi A; Feldman A; Wang M; Marcar L; Citrin DE; Wu CL; Benes CH; Efstathiou JA; Willers H
Oncogene; 2018 May; 37(21):2793-2805. PubMed ID: 29511347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
